AutoSCT vs CAR-T for patients with relapsed LBCL in PR: the role of total metabolic tumor volume

Independent prognostic value of total metabolic tumor volume in advanced-stage FLПодробнее

CAR-T therapy versus autoSCT in DLBCLПодробнее

AlloHSCT for R/R LBCL after CAR-T therapy failureПодробнее

Auto-transplant vs CAR-T: How should we sequence the therapy; who should receive therapy?Подробнее

Role of CAR T-Cell Therapy in Relapsed/Refractory ALLПодробнее

Limitations of CAR T-cell therapy for DLBCLПодробнее

Evaluating the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCLПодробнее

Assessing metabolic tumor volume as a prognostic marker before CAR-T therapy for DLBCLПодробнее

CAR-T therapy vs autologous transplantation in R/R DLBCLПодробнее

GOYA trial: Prognostic value of metabolic tumor volume in DLBCLПодробнее

CAR T Cell Therapy in Relapsed/Refractory DLBCLПодробнее

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cellsПодробнее

CAR T-Cell Therapy: Relapsed/Refractory ALLПодробнее

Understanding & predicting outcomes in CAR T-cell therapy for aggressive lymphoma | Steven Bair, MDПодробнее

Christian Gisselbrecht | EBMT 2019 | Autologous stem cell transplant versus CAR T in R/R DLBCLПодробнее

Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive LymphomasПодробнее

Challenges Remain to be Addressed With CAR T-Cell Therapy in DLBCLПодробнее

Can CAR-T cells replace ASCT in DLBCL?Подробнее

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALLПодробнее